Small Company Offering and Sale of Securities Without Registration (d)
January 27 2020 - 4:31PM
Edgar (US Regulatory)
o
NoneEntity Type | 0001404281 | Tokai Pharmaceuticals, Inc. Tokai Pharmaceuticals Inc |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
| Name of Issuer |
Novus Therapeutics, Inc. |
| Jurisdiction of Incorporation/Organization |
| DELAWARE |
| |
| Year of Incorporation/Organization |
| |
x
| Over Five Years Ago |
| |
o
| Within Last Five Years (Specify Year) | |
| |
o
| Yet to Be Formed | |
| 2. Principal Place of Business and Contact Information |
| Name of Issuer | |
| Novus Therapeutics, Inc. | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
| Irvine | CALIFORNIA | 92612 | (949) 238-8090 |
| Last Name | First Name | Middle Name |
| Flesher | Gregory | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Chimovits | Erez | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Cohen | Cheryl | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Katkin | Keith | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| McBride | John | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Lyons | Gary | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Turkel | Catherine | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Kuwahara | Jon | |
| Street Address 1 | Street Address 2 |
| 19900 MacArthur Boulevard | Suite 550 |
| City | State/Province/Country | ZIP/Postal Code |
| Irvine | CALIFORNIA | 92612 |
| Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
|
o
| Agriculture | | Health Care |
o
| Retailing |
| | Banking & Financial Services | |
o
| Biotechnology |
o
| Restaurants |
| |
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
| |
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
| |
o
| Investing | |
x
| Pharmaceuticals | |
o
| Telecommunications |
| |
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
| |
o
| Pooled Investment Fund
| | | | | Travel |
| |
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| | Real Estate | |
o
| Lodging & Conventions |
| |
o
| Commercial | |
o
| Tourism & Travel Services |
| |
o
| Construction | |
o
| Other Travel |
| |
o
| REITS & Finance |
o
| Other |
| |
o
| Residential | |
| |
o
| Other Real Estate | |
|
o
| Business Services | |
| | Energy | |
| |
o
| Coal Mining | |
| |
o
| Electric Utilities | |
| |
o
| Energy Conservation | |
| |
o
| Environmental Services | |
| |
o
| Oil & Gas | |
| |
o
| Other Energy | |
| Revenue Range | Aggregate Net Asset Value Range |
|
o
| No Revenues |
o
| No Aggregate Net Asset Value |
|
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
|
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
|
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
|
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
|
o
| Over $100,000,000 |
o
| Over $100,000,000 |
|
x
| Decline to Disclose |
o
| Decline to Disclose |
|
o
| Not Applicable |
o
| Not Applicable |
| 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
|
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
|
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
|
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
|
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
| |
o
| Investment Company Act Section 3(c) |
|
x
| New Notice | Date of First Sale | 2020-01-14 |
o
| First Sale Yet to Occur |
| Does the Issuer intend this offering to last more than one year? |
o
| Yes |
x
| No |
| 9. Type(s) of Securities Offered (select all that apply) |
|
o
| Pooled Investment Fund Interests |
o
| Equity |
|
o
| Tenant-in-Common Securities |
o
| Debt |
|
o
| Mineral Property Securities |
x
| Option, Warrant or Other Right to Acquire Another Security |
|
x
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
o
| Other (describe) |
| | |
| 10. Business Combination Transaction |
| Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
| |
| Clarification of Response (if Necessary) | |
| |
| Minimum investment accepted from any outside investor | $ 0 USD |
| Recipient | Recipient CRD Number |
x
| None |
| H.C. Wainwright & Co., LLC | |
| (Associated) Broker or Dealer |
o
| None | (Associated) Broker or Dealer CRD Number |
o
| None |
| H.C. Wainwright & Co., LLC | 375 |
| Street Address 1 | Street Address 2 |
| 430 Park Avenue | |
| City | State/Province/Country | ZIP/Postal Code |
| New York | NEW YORK | 10022 |
| State(s) of Solicitation |
x
| All States |
o
| Foreign/Non-US |
| |
| 13. Offering and Sales Amounts |
| Total Offering Amount | $ 5828999 USD |
o
Indefinite |
| Total Amount Sold | $ 862278 USD | |
| Total Remaining to be Sold | $ 4966721 USD |
o
Indefinite |
| |
| Clarification of Response (if Necessary) |
| Includes proceeds from the sale of 6,898,224 warrants at $0.125 per warrant and the 6,898,224 shares of common stock issuable upon the exercise of such warrants at an exercise price of $0.72 per share. |
|
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
| |
| | Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 10 |
| 15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
| Sales Commissions | $ 60359 USD |
o
| Estimate |
| Finders' Fees | $ 0 USD |
o
| Estimate |
| |
| Clarification of Response (if Necessary) |
| H.C. Wainwright & Co., LLC received the above sales commission in connection with the sale of the warrants. |
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| | $ 0 USD |
o
Novus Therapeutics (NASDAQ:NVUS) Historical Stock Chart From Mar 2024 to Apr 2024
Novus Therapeutics (NASDAQ:NVUS) Historical Stock Chart From Apr 2023 to Apr 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|